Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Neuronetics ( (STIM) ) has shared an announcement.
Neuronetics announced its preliminary financial results for 2024 and issued guidance for 2025, following its acquisition of Greenbrook TMS Inc. The company expects a 12% to 19% increase in revenue for 2025 and aims to achieve cash flow breakeven by the third quarter. The acquisition is seen as a transformative step, combining Neuronetics’ technology with Greenbrook’s clinic network to enhance revenue growth and cost efficiency. Neuronetics also highlighted its Better Me Provider program and recent FDA clearance for its NeuroStar therapy as adjunct treatment for adolescent depression, expanding its market significantly.
More about Neuronetics
Neuronetics, Inc. is a global leader in neuroscience, focusing on providing treatment options for mental health through its NeuroStar Advanced Therapy system. This non-drug, noninvasive treatment is designed to improve the quality of life for patients with neurohealth conditions when traditional medications have not been effective.
YTD Price Performance: 14.77%
Average Trading Volume: 426,789
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $54.84M
See more data about STIM stock on TipRanks’ Stock Analysis page.
